In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Making a comeback after a negative experience with the US Food and Drug Administration

This article was originally published in RAJ Devices

Executive Summary

Negative feedback from the US Food and Drug Administration does not necessarily mean disaster. Glenn Neuman tells companies how to get back on their feet after a rejection.

You may also be interested in...



Clinica 100: What lies ahead for US device regulation

The jury is still out as to how the US regulatory system is going to evolve in the long term, but change it will. As the FDA gathers feedback on the IOM's damning report on the 510(k) system and the recommended changes, Glenn Neuman, director of scientific affairs at New World Regulatory Solutions*, details what to expect in the short term

Complaint handling: a window into the soul of your quality system

An inadequate complaint handling system is a frequent shortcoming highlighted in US Food and Drug Administration warning letters. Glenn Neuman of New World Regulatory Solutions gives some pointers on how to strengthen your quality system and overcome one of the most frequent stumbling blocks for medtech companies.

Complaint handling: a window into the soul of your quality system

An inadequate complaint handling system is a frequent shortcoming highlighted in US Food and Drug Administration warning letters. Glenn Neuman of New World Regulatory Solutions gives some pointers on how to strengthen your quality system and overcome one of the most frequent stumbling blocks for medtech companies.

UsernamePublicRestriction

Register

SC096163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel